Previous 10 | Next 10 |
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the effi...
Gainers: IVAC +7.3%. ERYP +7.3%. FATE +5.3%. CHX +4.8%. XP +3.9%. Losers: CMTL -12.4%. SABR -5.4%. MTCR -2.6%. ZY -2.1%. HAIN -1.9%. For further details see: IVAC, ERYP, CMTL and SABR among after hours movers
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +71%. Aehr Test (NASDAQ:AEHR) +36%. Unique Fabricating (NYSE:UFAB) +32%. Meredith (NYSE:MDP) +26%. Paltalk (NASDAQ:PALT) +24%. Marin Software (NASDAQ:MRIN) +22%. ReWalk Robotics (NASDAQ:RWLK) +20%. Metacrine (NASDAQ:MTCR) +17%. Naked Brand Group (NASDAQ:...
Gainers: Leap Therapeutics (NASDAQ:LPTX) +23%, aTyr Pharma (NASDAQ:LIFE) +16%, Metacrine (NASDAQ:MTCR) +9%, MedAvail Holdings (NASDAQ:MDVL) +7%. Losers: Silverback Therapeutics (NASDAQ:SBTX) -28%, Aerie Pharmaceuticals (NASDAQ:AERI) -27%,...
Gainers: TMC +8.2%. LAUR +7.6%. LPTX +6.7%. TTD +5.9%. GREE +4.4%. Losers: AERI -15.3%. TWKS -4.8%. TVTX -4.3%. PEGA -3.9%. MTCR -3.5% For further details see: LAUR, LPTX, AERI and TWKS among after hours movers
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Exceeded enrollment target of 180 total patients Interim data from the first 60 patients expected early in the fourth quarter of 2021 Topline MET642 trial results from all patients are anticipated in the first half of 2022 SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSW...
Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies f...
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive o...
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021 Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes on track to be reported in the fourth...
News, Short Squeeze, Breakout and More Instantly...
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...